Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: MAPP BIOPHARMACEUTICAL, INC.
Awarding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Funding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Period of performance: 2018-09-25 to 2024-06-30
Current total value of award: $56704950
Description: ADVANCE MBP134, A COCKTAIL OF TWO HUMAN MONOCLONAL ANTIBODIES (MBP047 AND MBP087), AS A POTENTIAL MEDICAL COUNTERMEASURE TO TREAT ACTIVE INFECTIONS OF SUDAN VIRUS